Cite
HARVARD Citation
Tanaka, H. et al. (2021). Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first‐line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401). Thoracic cancer. 12 (14), pp. 2113-2121. [Online].